This title appears in the Scientific Report :
1999
Please use the identifier:
http://hdl.handle.net/2128/3746 in citations.
Uptake kinetics of the somatostatin receptor ligand (86Y)DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
Uptake kinetics of the somatostatin receptor ligand (86Y)DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
[[sup 90]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide ([[sup 90]Y]SMT487) has been suggested as a promising radiotherapeutic agent for somatostatin receptor-expressing tumours. In order to quantify the in vivo parameters of this compound and the radiation doses delivered to healthy organs, the analogue...
Saved in:
Personal Name(s): | Rösch, F. |
---|---|
Herzog, H. / Stolz, B. / Brockmann, J. / Köhle, M. / Mühlensiepen, H. / Marbach, P. / Müller-Gärtner, H.-W. | |
Contributing Institute: |
Institut für Medizin; IME Institut für Nuklearchemie; INC |
Published in: | European journal of nuclear medicine and molecular imaging, 26 (1999) S. 353 - 366 |
Published in: |
European Journal of Nuclear Medicine; 1999, Vol. 26 Issue 4, p358 |
Imprint: |
Heidelberg [u.a.]
Springer-Verl.
1999
|
Physical Description: |
353 - 366 |
Document Type: |
Journal Article |
Research Program: |
Signaltransduktion Nukleare Daten und Radionuklidproduktion Radiopharmazeutische Chemie |
Series Title: |
European Journal of Nuclear Medicine
26 |
Subject (ZB): | |
Link: |
OpenAccess |
Publikationsportal JuSER |
[[sup 90]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide ([[sup 90]Y]SMT487) has been suggested as a promising radiotherapeutic agent for somatostatin receptor-expressing tumours. In order to quantify the in vivo parameters of this compound and the radiation doses delivered to healthy organs, the analogue [[sup 86]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide was synthesised and its uptake measured in baboons using positron emission tomography (PET). [[sup 86]Y]DOTADPhe[sup 1]-Tyr[sup 3]-octreotide was administered at two different peptide concentrations, namely 2 and 100 micro g peptide per m2 body surface. The latter concentration corresponded to a radiotherapeutic dose. In a third protocol [[sup 86]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide was injected in conjunction with a simultaneous infusion of an amino acid solution that was high in L-lysine in order to lower the renal uptake of radioyttrium... |